Redeye reviews BioInvent's Q4 report 2025. Following a string of positive readouts from BI-1206 and BI-1808 in November - January, in particular in ovarian cancer, we increased our base case to SEK90 (SEK80). In the conference call yesterday, BioInvent presented new data from the BI-1206 triplet trial in lymphoma. With 20 patients, the ORR was 80% (same as before). 2026 will be a year with important phase IIa readouts across all active programmes.
LÄS MER
